Appearing as a promising breakthrough in the struggle against obesity, the drug is attracting considerable interest . This treatment combines effects of two recognized GLP-1 binding agonists, dulaglutide , plus an additional glucose-dependent incretin component. Initial study data have shown impressive weight reduction in patients with a high B… Read More